Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

  • There is currently no data for INDV

Director/PDMR Shareholding

4 Mar 2024 09:35

RNS Number : 4585F
Indivior PLC
04 March 2024
 

INDIVIOR PLC (THE 'COMPANY')

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

The relevant notification set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.

The Company announces that it was notified on March 1, 2024, that the following Persons discharging managerial responsibilities ('PDMR') exercised an option over ordinary shares of $0.50 each in the Company ('Shares'). The number of shares exercised are outlined below.

Name

Date of Grant

Number of Shares

Exercise Priceper Share

Date of Exercise

Kathryn Hudson

December 4, 2020

1,875

£4.80

March 1, 2024

Hillel West

December 4, 2020

2,250

£4.80

March 1, 2024

Following the transactions, Kathryn Hudson retained her interest in the shares and holds a beneficial interest in 32,858 Shares. On March 1, 2024, Hillel West sold the shares resulting from the option exercise and holds a beneficial interest in 27,733 Shares.

Kathryn Hudson

Company Secretary

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Kathryn Hudson

2

 

Reason for the notification

 

a)

 

Position/status

  

PDMR - Company Secretary

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Indivior PLC

b)

 

LEI

 

213800V3NCQTY7IED471

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of US$0.50

 

 

GB00BN4HT335

b)

 

Nature of the transaction

Exercise of a share option under the ShareSave Plan

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

£4.80

1875

d)

 

Aggregated information

 

- Aggregated volume

 

 - Price

 

N/A

e)

 

Date of the transaction

March 1, 2024

f)

 

Place of the transaction

 

Outside a trading venue

 

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Hillel West

2

 

Reason for the notification

 

a)

 

Position/status

  

PDMR - Chief Manufacturing and Supply Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Indivior PLC

b)

 

LEI

 

213800V3NCQTY7IED471

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of US$0.50

 

 

GB00BN4HT335

b)

 

Nature of the transaction

Exercise of a share option under the ShareSave Plan and sale of the resulting shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volumes(s)

1. £4.80

2,250

2. £17.61

2,250

d)

 

Aggregated information

 

- Aggregated volume

 

 - Price

 

N/A

e)

 

Date of the transaction

March 1, 2024

f)

 

Place of the transaction

 

1. Outside a trading venue

2. London Stock Exchange (XLON)

 

 

This notification is made in accordance with the requirements of the Market Abuse Regulation.

 

Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUPUCWWUPCUBC
Date   Source Headline
22nd Nov 20237:00 amRNSTransaction in Own Shares
21st Nov 202311:51 amRNSDirector/PDMR Shareholding
21st Nov 20237:00 amRNSTransaction in Own Shares
20th Nov 20233:33 pmRNSDirector/PDMR Shareholding
20th Nov 20232:55 pmRNSIndivior to Participate in Upcoming Investor Event
20th Nov 202312:56 pmRNSDirector/PDMR Shareholding
20th Nov 20239:37 amRNSHolding(s) in Company
17th Nov 202311:37 amRNSShare Repurchase Program
17th Nov 202310:00 amRNSHolding(s) in Company
17th Nov 20239:59 amRNSHolding(s) in Company
17th Nov 20237:00 amRNSAmendment to Relationship Agreement with Scopia
16th Nov 20232:00 pmRNSIndivior to Participate in Upcoming Conference
15th Nov 20232:54 pmRNSHolding(s) in Company
15th Nov 202310:23 amRNSHolding(s) in Company
10th Nov 202310:17 amRNSBlock listing Interim Review
9th Nov 20237:01 amRNSAppointment of Independent Non-Executive Director
9th Nov 20237:00 amRNS3rd Quarter Results
1st Nov 20234:00 pmRNSIndivior to Participate in Upcoming Conference
26th Oct 202311:51 amRNSHolding(s) in Company
23rd Oct 20237:00 amRNSIndivior settles Antitrust MDL with DPs
13th Oct 202312:14 pmRNSHolding(s) in Company
5th Oct 20233:30 pmRNSNotice of Results
21st Aug 20237:00 amRNSIndivior settles Antitrust MDL with End Payors
1st Aug 20234:00 pmRNSTotal Voting Rights
27th Jul 20237:00 amRNSHalf-year Report
26th Jul 20234:00 pmRNSHolding(s) in Company
24th Jul 20234:00 pmRNSHolding(s) in Company
10th Jul 20234:00 pmRNSHolding(s) in Company
5th Jul 20234:00 pmRNSHolding(s) in Company
30th Jun 20234:00 pmRNSDirector Declaration
29th Jun 20234:00 pmRNSHolding(s) in Company
27th Jun 202311:00 amRNSNotice of Results
21st Jun 20234:00 pmRNSHolding(s) in Company
16th Jun 20234:00 pmRNSHolding(s) in Company
15th Jun 20234:00 pmRNSHolding(s) in Company
14th Jun 20234:00 pmRNSHolding(s) in Company
14th Jun 20234:00 pmRNSHolding(s) in Company
13th Jun 20234:00 pmRNSHolding(s) in Company
12th Jun 20237:00 amRNSIndivior to Commence Trading on Nasdaq
7th Jun 20233:45 pmRNSHolding(s) in Company
2nd Jun 20235:17 pmRNSIndivior settles antitrust MDL with states and DC
1st Jun 20239:11 amRNSTotal Voting Rights
26th May 20234:20 pmRNSHolding(s) in Company
25th May 20232:30 pmRNSIndivior to Participate in Upcoming Conferences
24th May 20233:05 pmRNSHolding(s) in Company
23rd May 20236:05 pmRNSIndivior Files Form 20-F for US Listing
23rd May 20232:42 pmRNSHolding(s) in Company
23rd May 20238:30 amRNSHolding(s) in Company
23rd May 20237:00 amRNSUS FDA Approves OPVEE
12th May 20232:56 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.